GLP-1 Pharmaceutical Composition with SNAC for Oral Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current GLP-1 formulations, particularly oral semaglutide tablets, suffer from low bioavailability, poor permeability across the gastrointestinal membrane, and require multiple daily injections, leading to discomfort and high production costs, with potential risks from non-proteinogenic amino acids.
Innovation Solution
A novel pharmaceutical composition comprising a GLP-1 compound and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid (NAC), specifically modified with a fatty diacid substituent linked to the E-amino group of Lys residue, enhancing transmembrane absorption and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If GLP-1 compounds are administered orally, then patient compliance is improved and production costs are reduced, but bioavailability is very low due to poor permeability across the gastrointestinal membrane
Solution Approach 1:
The patent uses SNAC (sodium salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid) as an intermediary substance that facilitates the absorption of GLP-1 compounds across the gastrointestinal membrane. SNAC acts as a mediator that enables the poorly permeable GLP-1 compound to cross the membrane effectively, thereby improving bioavailability while maintaining oral administration benefits
Solution Approach 2:
The invention creates a composite pharmaceutical composition containing both the GLP-1 compound and SNAC salt. This composite formulation combines two substances with complementary properties: the GLP-1 compound provides therapeutic activity while SNAC enhances membrane permeability, resulting in a formulation that achieves both oral administrability and adequate bioavailability
2Reliability
If injectable formulations are used, then bioavailability is improved, but patient compliance deteriorates due to discomfort from multiple daily injections
Solution Approach 1:
SNAC serves as an intermediary that enables oral administration to achieve bioavailability levels comparable to or exceeding injectable formulations. By facilitating gastrointestinal membrane permeation, SNAC allows the oral route to deliver adequate drug exposure without the discomfort of injections
Solution Approach 2:
The invention changes the administration route parameter from parenteral (injection) to oral while compensating for the inherent disadvantage of oral administration. The presence of SNAC alters the absorption parameters, enabling the oral formulation to achieve therapeutic blood concentrations that would otherwise require injection
3Ease of manufacture
If separate granulation of GLP-1 peptide and NAC salt is performed, then manufacturing process is simplified, but mixing uniformity deteriorates
Solution Approach 1:
The patent combines the GLP-1 compound and SNAC salt into a single granulation process rather than performing separate granulations followed by blending. This merged granulation approach ensures thorough mixing of the components during the granulation step itself, achieving uniform distribution while maintaining manufacturing simplicity
Solution Approach 2:
The invention performs the mixing action during the granulation process itself, which is a preliminary step before tablet compression. By incorporating the mixing function into the granulation step, the formulation achieves uniform distribution of components before the final compression step, eliminating the need for separate blending operations
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition exhibits improved therapeutic effects, longer half-life, faster dissolution, higher bioavailability, and better physicochemical stability compared to existing semaglutide tablets.
Implementation Method 1
enhancing transmembrane absorption and stability
Implementation Method 2
specifically modified with a fatty diacid substituent linked to the E-amino group of Lys residue
Data Source
AI summary
The present invention relates to a pharmaceutical composition of a GLP-1 compound and a preparation method therefor. In particular, the present invention relates to a pharmaceutical composition comprising a GLP-1 compound and salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid (NAC). The pharmaceutical composition has excellent efficacy, good bioavailability, excellent dissolution, and satisfactory physical stability and chemical stability.